Hibercell
is a New York-based biotechnology company that develops therapeutic molecules for the treatment of metastatic cancer... Read moreHibercell
is a New York-based biotechnology company that develops therapeutic molecules for the treatment of metastatic cancer... Read more
News
May 21, 2026
StreetInsider
Press Release: Hibercell : HiberCell to Present Preliminary Results from the Phase 1b Trial of GCN2 Activator HC-7366 when Combined with WELIREG (belzutifan) for the Treatment of Late-Line Clear Cell Renal Cell Carcinoma (ccR
Apr 14, 2026
GlobeNewswire
Press Release: Hibercell : HiberCell to Present Preclinical Data Demonstrating the Enhanced Antitumor Activity of HC-7366 in Combination with VEGFR-TKIs in Clear Cell Renal Cell Carcinoma (ccRCC)
Nov 04, 2025
PR Newswire
Press Release: Hibercell : AVEO Oncology, an LG Chem company, and HiberCell Enter Into an Exclusive Development and Option Agreement for First-in-Human Compound
May 27, 2025
GlobalNewswire
Press Release: Hibercell : HiberCell Announces Successful Completion of Dose Escalation and Enrollment Update for Ph1b Study Evaluating HC-7366 in Combination with WELIREG (belzutifan) in Advanced ccRCC
May 30, 2024
Pharmabiz
Hibercell: HiberCell doses first patient in phase 1b trial to evaluate HC7366 in combo with venetoclax and azacitidine to treat acute myeloid leukemia
May 01, 2024
Yahoo
Hibercell: HiberCell Announces First Patient Dosed in Clinical Collaboration with Merck, Evaluating HC-7366 in Combination with WELIREG (belzutifan) in patients with advanced ccRCC
Apr 05, 2024
StreetInsider
Press Release: Hibercell : HiberCell Announces Recent Publication and Poster Presentations for its Novel GCN2 Activator, HC-7366
Dec 15, 2023
Life Care News
Hibercell: HiberCell Announces Presentation at ASH, Highlighting
Dec 06, 2023
Pharamceutical Technology
Hibercell: Merck partners with HiberCell for Phase Ib renal carcinoma trial
Nov 27, 2023
StreetInsider
Press Release: Hibercell : HiberCell Announces Successful Completion and Interim Results of Phase 1 Study of Novel PERK Inhibitor, HC-5404, in Solid Tumors and Maps Forward Path as Monotherapy and in Combinations
